Dyadic (AMEX:DIL)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Dyadic Charts. Click Here for more Dyadic Charts.](/p.php?pid=staticchart&s=A%5EDIL&p=8&t=15)
Dyadic International, Inc. (AMEX:DIL), a biotechnology
company engaged in the development, manufacture and sale of biological
products, today announced changes to its Scientific Advisory Board
(SAB).
Joining Dyadic's SAB are Arnold Demain, Ph.D., Professor of
Industrial Microbiology, Emeritus, Massachusetts Institute of
Technology, Carlos Barbas, III, Ph.D., Kellogg Professor and Chair of
Molecular Biology and Chemistry at The Scripps Research Institute
(TSRI), and Joseph Villafranca, Ph.D., Executive Vice President,
Pharmaceutical Development and Operations, Neose Technologies, Inc.
Leaving Dyadic's SAB are Edward McGuire, Ph.D., former Vice
President of Research & Development, Neose Technologies, Inc., and
Michael Koslowski, Ph.D., Chief Scientist, Kreido Laboratories.
"The new SAB members fit exceptionally well into Dyadic's strategy
for the future and will help guide the company to select the best
opportunities among the numerous fields where Dyadic's technologies
can be applied," commented Mark Emalfarb, Dyadic's President and CEO.
"We are pleased to welcome these eminent scientists and look forward
to their contributions to the advancement of Dyadic's C1 Host
Technology and commercialization efforts of new and existing products
and processes." Drs. Demain, Barbas, and Villafranca join other
scientific leaders on Dyadic's SAB, which include chairman Dr. Richard
Lerner, Dr. Gerry Fink, and Drs. Arkady Sinitsyn, Peter Punt and Cees
van den Hondel. "Departing SAB members, Drs. McGuire and Koslowski
played an important role in advancing Dyadic's science and technology.
Their scientific guidance and dedicated service over the years are
greatly appreciated and we wish them well in their future endeavors,"
added Mark Emalfarb.
Bios for Drs. Demain, Barbas and Villafranca follow below. For
complete bios of all of Dyadic's SAB's current members, please visit
Dyadic's website at http://www.dyadic-group.com.
Arnold Demain, Ph.D.
Dr. Demain has been in the forefront of industrial microbiology
and biotechnology for over four decades and has been involved in the
research and commercialization of a number of fermentation based
pharmaceutical processes. He is currently a Fellow at Drew
University's Charles A. Dana Institute for Scientists Emeriti.
Previously, Dr. Demain was at the Massachusetts Institute of
Technology (MIT) for 32 years, where he most recently served as
Professor of Industrial Microbiology in the Department of Biology.
Before going to MIT, Dr. Demain spent fifteen years at Merck & Co.,
where he held various positions in R&D and management focused on
fermentation microbiology. His leadership in the area of fermentation
is evidenced by over 470 publications, 10 books of which he is
coeditor or coauthor, 20 U.S. patents and his election to the
presidency of the Society for Industrial Microbiology in 1990,
membership in the National Academy of Sciences in 1994, the Mexican
Academy of Sciences in 1997 and the Hungarian Academy of Sciences in
2001. Dr. Demain received his Ph.D. in Microbiology from University of
California.
Carlos Barbas, Ph.D.
Dr. Barbas is a Professor of The Scripps Research Institute,
Departments of Molecular Biology and Chemistry and The Skaggs
Institute for Chemical Biology. He holds the Janet and W. Keith
Kellogg II endowed Chair in Molecular Biology and Chemistry. Dr.
Barbas has received honours including the Investigator Award from the
Cancer Research Institute, The Scholar Award of the American
Foundation for AIDS Research, and the Presidential Green Chemistry
Challenge Award. He is the author of over 200 scientific articles and
is a named inventor on 32 issued U.S. patents. Key accomplishments in
the area of biotechnology pioneered by Dr. Barbas and his colleagues
include the development of the first human antibody phage libraries,
development of the first synthetic antibodies, the development of the
first artificial transcription factors capable of regulating
endogenous genes, and chemically programmed antibodies-the CovX core
technology. Dr. Barbas received his Ph.D. in Organic Chemistry from
Texas A&M University.
Joseph Villafranca, Ph.D.
Dr. Villafranca has served as Executive Vice President,
Pharmaceutical Development and Operations at Neose Technologies, Inc.,
since February 2004. He joined Neose in October 2002 as Senior Vice
President, Pharmaceutical Development and Operations. From 1992 to
2002 he held various positions at Bristol-Myers Squibb, serving most
recently as Vice President of Biologics Strategy and
Biopharmaceuticals Operations. Prior to Bristol-Myers, Dr. Villafranca
spent 20 years at Penn State University, including eight years as the
Evan Pugh Professor of Chemistry. Dr. Villafranca earned a B.S. in
Chemistry from the State University of New York and a Ph.D. in
Biochemistry/Chemistry from Purdue University. He completed his
post-doctoral training in Biophysics at the Institute for Cancer
Research in Philadelphia.
About Dyadic
Dyadic International, Inc., is engaged in the development,
manufacture and sale of biological products (proteins, enzymes,
peptides and other bio-molecules), as well as the licensing of its
enabling proprietary technology to business collaborators for the
discovery, development and manufacture of biological products from
genes. Dyadic markets its products and services for applications in
the textile, chemical, agricultural, pulp & paper, pharmaceutical,
biotechnology and other industries, using its proprietary C1 Host
Technology and C1 Expression and Screening Systems for the discovery,
development and production of biological products.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements involve
risks and uncertainties that could cause our actual results,
performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, please see our filings from time to time with the
Securities and Exchange Commission, which are available free of charge
on the SEC's web site at http://www.sec.gov, including our Annual
Report on Form 10-KSB for the year ended December 31, 2004, and our
Quarterly Report for the quarter ended June 30, 2005 on Form 10-QSB.
Except as required by law, we expressly disclaim any intent or
obligation to update any forward-looking statements.